Zero-order controlled release of ciprofloxacin-HCl from a reservoir-based, bioresorbable and elastomeric device

Journal of Controlled Release

Volumn 146, Issue 3, 2010, Pages 356-362

  Tobias, Irene S ^a   Lee, Heejin ^a   Engelmayr, George C ^b   Macaya, Daniel ^c   Bettinger, Christopher J ^a   Cima, Michael J ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^c Cornell University   (United States)

Author keywords

Biodegradable polymers; Ciprofloxacin; Elementary osmotic pump; Insertable devices; PGS

Indexed keywords

BIODEGRADABLE ELASTOMERS; BIORESORBABLE; CELLULOSE ACETATES; CIPROFLOXACIN; COMMONLY USED; CONTROLLED RELEASE; DIFFUSION MECHANISMS; DRUG RELEASE; IN-VITRO; INSERTABLE DEVICES; ORDERS OF MAGNITUDE; ORIFICE SIZE; OSMOTIC PUMPS; PERFORMANCE EVALUATION; PGS; RELEASE RATE; RESORBABLE; SEBACIC ACID; TUBULAR GEOMETRY; WATER PERMEABILITY;

ANTIBIOTICS; DRUG DELIVERY; GLYCEROL; ORIFICES; OSMOSIS; PUMPS; RESERVOIRS (WATER);

BIODEGRADABLE POLYMERS;

CELLULOSE ACETATE; CIPROFLOXACIN; ELASTOMER; GLYCEROL DERIVATIVE; GLYCEROL SEBACIC ACID COPOLYMER; SEBACIC ACID; UNCLASSIFIED DRUG;

ARTICLE; BIODEGRADABILITY; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; OSMOSIS; OSMOTIC PUMP; PRIORITY JOURNAL; WATER PERMEABILITY;

ANTI-INFECTIVE AGENTS; BIOCOMPATIBLE MATERIALS; CIPROFLOXACIN; DECANOATES; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; GLYCEROL; POLYMERS;

EID: 77956292976     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.05.036     Document Type: Article

References (42)

1. Langer R. Implantable controlled release systems. Pharm. Ther. 1982, 21:35-51.
2. Sershen S., West J. Implantable, polymeric systems for modulated drug delivery. Adv. Drug Deliv. Rev. 2002, 54:1225-1235.
3. Henry R., Patterson L., Avery N., Tanzola R., Tod D., Hunter D., et al. Absorption of alkalized intravesicle lidocaine in normal and inflamed bladders: a simple method for improving bladder anesthesia. J. Urol. 2001, 165:1900-1903.
4. Yamamoto M., Hibi H., Satoshi K., Miyake K. Chronic bacterial prostatitis treated with intraprostatic injection of antibiotics. Scand. J. Urol. Nephrol. 1996, 30:199-202.
5. Guercini F., Pajoncini C., Bard R., Fiorentino F., Bini V., Costantini E., Porena M. Echoguided drug infiltration in chronic prostatitis: results of a multi-centre study. Arch. Ital. Urol. Androl. 2005, 77:87-92.
6. Fowler C.J. Intravesicle treatment of overactive bladder. Urology 2000, 55:60-64.
7. Santus G., Baker R.W. Osmotic drug delivery: a review of the patent literature. J. Control. Release 1995, 35:1-21.
8. Verma R.K., Mishra B., Garg S. Osmotically controlled oral drug delivery. Drug Dev. Ind. Pharm. 2000, 26:695-708.
9. Ranade V.V. Drug delivery systems. 4. Implants in drug delivery. J. Clin. Pharm. 1990, 30:871-889.
10. Verma R.K., Krishna D.M., Garg S. Formulation aspects in the development of osmotically controlled oral drug delivery systems. J. Control. Release 2002, 79:7-27.
11. Theeuwes F. Elementary osmotic pump. J. Pharm. Sci. 1975, 64:1981-1987.
12. Verma R.K., Arora S., Garg S. Osmotic pumps in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 2004, 21:477-520.
13. Wright J.C., Leonard S.T., Stevenson C.L., Beck J.C., Chen G., Jao R., et al. An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. J. Control. Release 2001, 75:1-10.
14. Fisher D.M., Kellett N., Lenhardt R. Pharmacokinetics of an implanted osmotic pump delivering sufentanil for the treatment of chronic pain. Anesthesiology 2003, 99:929-937.
15. Djalilian H.R., Caicedo E., Lessan K., Grami V., Le C.T., Spellman S.R., et al. Efficacy of an osmotic pump delivered, GM-CSF-based tumor vaccine in the treatment of upper aerodigestive squamous cell carcinoma in rats. Cancer Immunol. Immunother. 2007, 56:1207-1214.
16. Ryu W., Huang Z., Prinz F.B., Goodman S.B., Fasching R. Biodegradable micro-osmotic pump for long-term and controlled release of basic fibroblast growth factor. J. Control. Release 2007, 124:98-105.
17. Amsden B. Curable, biodegradable elastomers: emerging biomaterials for drug delivery and tissue engineering. Soft Matter 2007, 3:1335-1348.
18. Bruggeman J.P., Bettinger C.J., Nijst C.L.E., Kohane D.S., Langer R. Biodegradable xylitol-based polymers. Adv. Mater. 2008, 20:1922-1927.
19. Bettinger C.J., Bruggeman J.P., Borenstein J.T., Langer R.S. Amino alcohol-based degradable poly(ester amide) elastomers. Biomaterials 2008, 29:2315-2325.
20. Gu F., Neufeld R., Amsden B. Osmotic-driven release kinetics of bioactive therapeutic proteins from a biodegradable elastomer are linear, constant, similar, and adjustable. Pharm. Res. 2006, 23:782-789.
21. Gu F., Neufeld R., Amsden B. Sustained release of bioactive therapeutic proteins from a biodegradable elastomeric device. J. Control. Release 2007, 117:80-89.
22. Wang Y., Ameer G.A., Sheppard B.J., Langer R. A tough biodegradable elastomer. Nat. Biotechnol. 2003, 20:602-606.
23. Wang Y., Kim Y.M., Langer R. In vivo degradation characteristics of poly(glycerol sebacate). J. Biomed. Mater. Res. A 2003, 66:192-197.
24. Motlagh D., Yang J., Lui K.Y., Webb A.R., Ameer G.A. Hemocompatibility evaluation of poly(glycerol-sebacate) in vitro for vascular tissue engineering. Biomaterials 2006, 27:4315-4324.
25. Bettinger C.J., Weinber E.J., Kulig K.M., Vacanti J.P., Wang Y., Borenstein J.T., Langer R. Three-dimensional microfuidic tissue-engineering scaffolds using a flexible biodegradable polymer. Adv. Mater. 2006, 18:165-169.
26. Kim M.S., Ahn H.H., Shin Y.N., Cho M.H., Khang G., Lee H.B. An in vivo study of the host tissue response to subcutaneous implantation of PLGA- and/or porcine small intestinal submucosa-based scaffolds. Biomaterials 2007, 28:5137-5143.
27. Samanidou V.F., Demetriou C.F., Papadoyannis I.N. Direct detection of four fluoroquinolones, enoxacin, norfloxacin, ofloxacin and ciprofloxacin, in pharmaceuticals and blood serum by HPLC. Anal. Bioanal. Chem. 2003, 375:623-629.
28. Vyas S.P., Guleria R., Singh R. Development and in-vitro characterization of elementary osmotic pump bearing ciprofloxacin hydrochloride. East. Pharm. 1996, 167-169.
29. Ndovi T.T., Choi L., Caffo B., Parsons T., Baker S., Zhao M., et al. Quantitative assessment of seminal vesicle and prostate drug concentrations by use of a noninvasive method. Clin. Pharmacol. Ther. 2006, 80:146-158.
30. Anderson R.U., Fair W.R. Physical and chemical determinations of prostatic secretion in benign hyperplasia, prostatitis, and adenocarcinoma. Invest. Urol. 1976, 14:137-140.
31. Blacklock N.J., Beavis J.P. The response of fluid pH in inflammation. Br. J. Urol. 1978, 46:537-542.
32. Engelmayr G.C., Cheng M., Bettinger C.J., Borenstein J.T., Langer R., Freed L.E. Nat. Mater. 2008, 7:1003-1010.
33. Vranny J.D., Steward P.S., Suci P.A. Comparison of recalcitrance to ciprofloxacin and levofloxacin exhibited by Psudomonas aeruginosa biofilms displaying rapid-transport characteristics. Antimicrob. Agents Chemother. 1997, 41(6):1352-1358.
34. Melo M.J.P., Varanda F.R., Dohrn R., Marrucho I.M. Solubility of Ciprofloxacin and Moxifloxacin in Different Solvents: The Effect of the HCl Group. 2cd Mercosur Congress on Chemical Engineering 2005.
35. von Burkersroda F., Schedl L., Göpferich A. Why degradable polymers undergo surface erosion or bulk erosion. Biomaterials 2002, 23:4221-4231.
36. Göpferich A., Langer R. The influence of microstructure and monomer properties of the erosion mechanism of a class of polyanhydrides. J. Polym. Sci., A, Polym. Chem. 1993, 31:2445-2458.
37. Schaeffer A.J., Wendel E.F., Dunn J.K., Grayhack J.T. Prevalence and significance of prostatic inflammation. J. Urol. 1981, 125:215-219.
38. Nickel J.C. Inflammatory conditions of the male genitourinary track: prostatitis and related conditions, orchitis, and epididymitis. Campbell-Walsh Urology 2007, 304-329. Elsevier, Philadelphia. 9th ed. A.J. Wein, L.R. Kavoussi, A.C. Novick, A.W. Partin, C.A. Peters (Eds.).
39. Bjerklund Johansen T.E., Grüneberg R.N., Guiber J., Hofstetter A., Lobel B., Naber K.G., Palou Redorta J., van Cangh P.J. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur. Urol. 1998, 34:457-466.
40. Older R.A., Watson L.R. Ultrasound anatomy of the normal male reproductive tract. J. Clin. Ultrasound 1996, 24:389-404.
41. Sandlow J.I., Winfield H.N., Goldstein M. Surgery of the scrotum and seminal vesicles. Campbell-Walsh Urology 2007, 1098-1128. Elsevier, Philadelphia. 9th ed. A.J. Wein, L.R. Kavoussi, A.C. Novick, A.W. Partin, C.A. Peters (Eds.).
42. Chin N., Neu H. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 1984, 25:319-326.